October 2014 FDA Recall Carbamazepine by Taro Pharmaceuticals U.s.a., Inc.
D-0049-2015 - Marketed without an Approved NDA/ANDA

This Class III drug recall was voluntarily initiated by Taro Pharmaceuticals U.s.a., Inc. on October 21, 2014 for the product Carbamazepine. The FDA reported the reason for recall as marketed without an approved nda/anda. The product was distributed in IL, OH, LA and the recall is currently terminated.

Recall Number: D-0049-2015

Reason for Recall
Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.
Initiated
10-21-2014
Reported
11-05-2014
Quantity
1,966 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Taro Pharmaceuticals U.S.A., Inc.
Carbamazepine Tablets USP, 200 mg, 1000 Tablets per Bottle, Rx only, Manufactured by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 26110 Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4005-3.

Batch or Lot Expiration Information

Lot# Lot 137393, exp. 10/2016